Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PROTEOMICS -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (228)	3/27/2001 12:06:07 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 539

MDS Proteomics and Partners HealthCare Form Clinical Alliance to Speed the Discovery of New Medicines TORONTO and BOSTON--(BW HealthWire)--March 27, 2001--MDS Proteomics Inc., an international biotechnology company focused on functional proteomics, and Partners HealthCare Inc., an integrated healthcare delivery system founded by Harvard Medical School teaching affiliates Massachusetts General Hospital and Brigham and Women's Hospital, today announced they have formed a clinical research alliance to gain a deeper understanding of how to utilize the study of protein-to-protein pathways to improve patient care. ``Partners HealthCare will provide us with invaluable insight into the realities of patient treatment issues,'' said Frank Gleeson, president and CEO, MDS Proteomics. ``This perspective brings clinical practicality to our functional proteomics research by getting to the heart of clinical treatment issues, further bridging the gap between genomics and new medicines.'' ``MDS Proteomics is advancing the development of new therapeutic and diagnostic products to treat disease through its drug discovery platform,'' said William F. Crowley, Jr., MD, director of clinical research at Massachusetts General Hospital. ``The enormous breadth and depth of our research at Massachusetts General and Brigham and Women's Hospitals are highly complementary to the proteomics expertise resident in MDS Proteomics and we envisage that this will contribute to speeding the discovery and development of clinically relevant products.'' MDS Proteomics also announced last week that it will open a facility in Boston, Massachusetts that will include a state-of-the-art laboratory encompassing the latest proteomics and bioinformatics instrumentation and technology. The proximity of this facility to Partners HealthCare will serve to foster a more productive relationship. About Proteomics Proteins regulate the activities of cells, tissues and organs. Interactions among proteins can trigger chemical reactions within cells that play a key role in diseases and ailments such as cancer, AIDS and depression. The emerging field of proteomics -- the study of protein location, interaction, structure and function -- aims to identify and characterize the proteins present in normal and diseased biological samples. Abnormalities in protein production or function have been connected to many diseases and health conditions, so the ability to modulate proteins represents an attractive target for drug design. About MDS Proteomics A leader in the emerging field of proteomic-enabled drug discovery, MDS Proteomics' approach is to determine how proteins function at the cellular level by understanding their interaction. MDS Proteomics has integrated functional proteomics and supercomputing to create a drug discovery platform to reveal cellular pathways, identify and validate novel targets and advance the development of new therapeutic and diagnostic products. MDS Proteomics is a majority-owned subsidiary of MDS Inc. About MDS Inc. MDS Inc. (NYSE: MDZ - news; TSE: MDS - news) is an international health and life sciences company that is focused on fighting disease in numerous ways. Its products and services include: laboratory testing, imaging agents for nuclear medicine testing, sterilization systems for medical and consumer products, research and clinical development services for planning and delivery of cancer treatment, analytical instruments to assist in the development of news drugs, and medical / surgical supplies. MDS employs more than 10,000 highly skilled people at its global operations on four continents. Detailed information about the company is available at the MDS Web site at www.mdsintl.com.